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Abstract
Background: There is robust clinical evidence to support offering early access to antiretroviral treatment (ART) to
all HIV-positive individuals, irrespective of disease stage, to both improve patient health outcomes and reduce HIV
incidence. However, as the global treatment guidelines shift to meet this evidence, it is still largely unknown if early
access to ART for all (also referred to as “treatment as prevention” or “universal test and treat”) is a feasible intervention in
the resource-limited countries where this approach could have the biggest impact on the course of the HIV epidemics.
The MaxART Early Access to ART for All (EAAA) implementation study was designed to determine the feasibility,
acceptability, clinical outcomes, affordability, and scalability of offering early antiretroviral treatment to all HIV-positive
individuals in Swaziland’s public sector health system.
Methods: This is a three-year stepped-wedge randomized design with open enrollment for all adults aged 18 years and
older across 14 government-managed health facilities in Swaziland’s Hhohho Region. Primary endpoints are retention and
viral suppression. Secondary endpoints include ART initiation, adherence, drug resistance, tuberculosis, HIV disease
progression, patient satisfaction, and cost per patient per year.
Sites are grouped to transition two at a time from the control (standard of care) to intervention (EAAA) stage at each
four-month step. This design will result in approximately one half of the total observation time to accrue in the
intervention arm and the other half in the control arm. Our estimated enrolment number, which is supported by
conservative power calculations, is 4501 patients over the course of the 36-month study period.
A multidisciplinary, mixed-methods approach will be adopted to supplement the randomized controlled trial and meet
the study aims. Additional study components include implementation science, social science, economic evaluation,
and predictive HIV incidence modeling.
Discussion: A stepped-wedge randomized design is a causally strong and robust approach to determine if providing
antiretroviral treatment for all HIV-positive individuals is a feasible intervention in a resource-limited, public sector
health system. We expect our study results to contribute to health policy decisions related to the HIV response in
Swaziland and other countries in sub-Saharan Africa.
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Background
The global community has made extraordinary strides in
scaling up treatment for people living with HIV/AIDS
over the past two decades. Since 2000, there has been a
30-fold increase in people accessing antiretroviral ther-
apy (ART) globally from 250,000 people to more than 17
million people in 2015 [1, 2]. The rate of new infections
globally has also come down in the last decade from 3.3
million new infections in 1998 to 2.1 million in 2015 [2].
This success has been driven, in part, by an unprece-
dented increase in financial resources, with annual fund-
ing levels increasing from US$5 billion in 2003 to
US$19.2 billion in 2014 [3].
However, despite the significant progress, the global
community is still far from ensuring that all people
living with HIV/AIDS (PLHIV) eligible for treatment are
receiving it. Moreover, without a significant reduction in
new infections, the number of individuals in need of
treatment will continue to expand, as will the costs of
HIV treatment programs [4, 5]. Identifying and imple-
menting effective prevention interventions to try and get
ahead of the epidemic is a crucial next step in the global
response to HIV.
Over the past several years, HIV research has demon-
strated that earlier and expanded access to ART could
have a significant impact on HIV incidence. Results from
the HIV Prevention Trials Network 052 (HPTN 052) trial
showed that early access to ART prevents onward trans-
mission of the virus to the uninfected partner in hetero-
sexual HIV-discordant couples. In 2011, the trial reported
not only a 96% decrease in HIV transmission, but also a
41% decrease in HIV-related morbidity from early initi-
ation of ART [6]. The results from the Strategic Timing of
Antiretroviral Therapy (START) trial in 2015 demon-
strated that the immediate initiation of ART was beneficial
for morbidity and mortality with no increased rate of
adverse effects [7]. In response to this growing body of
epidemiological evidence, World Health Organization
(WHO) 2015 treatment guidelines recommended ART
initiation for all HIV-positive individuals [8].
While the clinical impact of Early Access to ART for
All (EAAA) is evident, critical implementation questions
remain. Recently, results from the Treatment as Preven-
tion (TasP) Trial in rural KwaZulu-Natal in South Africa
did not demonstrate a difference in HIV incidence be-
tween communities randomized to either immediate
offer of ART for all HIV-positive individuals compared
to the standard of care [9]. The study results
demonstrated not only the need for high rates of
linkages to care following diagnosis, but also the import-
ance of understanding how to best deliver early ART in
southern Africa. As the latest WHO guidelines are
recommending EAAA [10] and countries in sub-Saharan
Africa start to follow this recommendation [11], the
critical question is no longer whether EAAA should be
implemented, but rather how to implement it in resource-
limited settings where the epidemic is most prevalent.
It remains unknown, however, what the impact of
EAAA policies will be on public sector health systems in
sub-Saharan Africa. The overall HIV treatment program
effectiveness in successfully treating HIV patients could
change, as could patient satisfaction, patients’ economic
welfare, and provider satisfaction. Policymakers in high
HIV prevalence countries and stakeholders in the inter-
national community require empirical evidence to assess
the feasibility and acceptability of EAAA policies, as well
as the clinical outcomes, affordability, and scalability of
national implementation of this intervention through
routine, public sector health systems.
This study was designed in response to questions
posed by Swaziland’s policymakers about the impact of
an EAAA policy on their national HIV/AIDS care and
treatment program. The study aims to generate the evi-
dence needed to more fully understand what is required
to successfully implement an EAAA strategy in a public
sector health system in sub-Saharan Africa.
Specific aims
This trial aims to:
1. quantify the causal impact of early access to ART
for all HIV-infected adults, irrespective of CD4
count or clinical staging, on ART retention and viral
suppression in a public sector health system;
2. quantify the causal impacts of EAAA on average
health care expenditures and resources use;
3. quantify the causal impacts of EAAA on patient
satisfaction, patients’ welfare, and provider satisfaction;
4. to establish the feasibility and acceptability of EAAA;
5. establish the role of PLHIV, traditional leaders, civil
society, and communities for implementing EAAA;
6. determine the social and institutional processes
throughout EAAA implementation to help interpret
differences in health service delivery and patient
experiences of ART initiation, adherence, and
retention before and after the intervention;
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7. estimate the potential change in HIV incidence and
ART program size if EAAA were to be implemented
nationwide in Swaziland; and
8. predict the long-term cost-effectiveness of EAAA.
Methods
Study design
This is a randomized seven-stepped-wedge design on
seven pairs (13 government clinics and one regional hos-
pital) in Hhohho Region (see Fig. 1) with open enroll-
ment for all adults aged ≥ 18 years.
The study sites include a mix of high-volume and low-
volume facilities (volume of patients) that are already
providing a comprehensive package of HIV care and
treatment services per Swaziland’s national adult HIV
treatment guidelines [12].
Sites are grouped to transition two at a time from the
control (national eligibility guidelines or current stand-
ard of care) to the intervention (EAAA) stage every four
months. As illustrated in Fig. 2, the study will enroll all
eligible HIV-positive patients who arrive at the facility in
Month 1. All sites will start in the standard of care stage
(“C”), and then each site will have a four-month transi-
tion period (“T”) to transition consecutively until all sites
are in the intervention (“I”) stage. The sites will start
implementing the intervention on the first day of the
transition period.
Individuals who arrive at one of the study facilities
during the control (“C”) stage will be offered ART
according to the current national guidelines. Sites will
follow the current national standard of care for HIV care
and treatment while in the control stage.
During the transition period (“T”) and the intervention
(“I”) stage, all HIV-positive patients will be offered ART
per the EAAA intervention (an offer of immediate ART
initiation irrespective of CD4). Study participants who
were already in pre-ART at the start of the study or who
were enrolled into pre-ART during the control stage ac-
cording to national standard of care will be offered ART
at their first follow-up appointment at their enrollment
site following the site’s transition to the intervention
stage. This way, everyone who is enrolled into the study
population will eventually be offered the EAAA
intervention (Fig. 3).
An additional file provides the protocol checklist (see
Additional file 1. SPIRIT checklist for the MaxART
EAAA Trial, indicating which manuscript page contains
each element of the study protocol).
Setting
Swaziland faces a prevalence rate of 31–32% among its
18–49-year-olds, but the epidemic disproportionately
affects women [13]. The recent Swaziland HIV Incidence
Measurement Survey highlighted that overall HIV inci-
dence is higher among women (3.1% for women and
1.7% for men) and highest of all in women 20–24 years
of age (4.2%) [13].
The Swaziland National AIDS Program (SNAP) has
been in existence since 2004 and has scaled up its pro-
gram each year, resulting in a significant increase in the
number of people on treatment. The country has made
great strides in their HIV response, including a robust
national ART program and expanding the immuno-
logical treatment eligibility criteria in their national HIV
treatment guidelines since 2010 to individuals with CD4
< 350 cells/mm3. In December 2015, the country further
expanded its eligibility criteria to CD4 < 500 cells/mm3
as per the WHO 2015 guidelines. At the end of December
2015, 147,274 adults were on treatment, which represents
more than 90% treatment coverage based on current
eligibility criteria (CD4 count > 500 cell/mm3) and
estimates of need [14].
Trial participants (inclusion and exclusion criteria)
All HIV-positive individuals who are aged 18 years or
older and are ART naïve—excluding pregnant or breast-
feeding women—who attend the health facilities
included in the study will be asked for their verbal con-
sent to enroll in the study. Those individuals whose CD4
is greater than the current national guidelines for ART
initiation and whose WHO stage is not 3 or 4 are the
primary study population. Written informed consent will
be secured for participation in social science research
and the economic evaluation.
Participants must be able and willing to give verbal
consent for trial participation. Individuals considered
unable to provide and participate in informed consent
include those with uncontrolled psychiatric disorders or
severe neurological impairment.
Fig. 1 Map of study sites in Hhohho Region
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Sample size
The primary study population will be 2008 newly diag-
nosed or returning pre-ART patients as defined by the
current national guidelines who are enrolled during the
control or the intervention stage over the 36-month
study period. In addition, 2493 patients with CD4 ≤ 350
cells/mm3 will be enrolled to form a total study popula-
tion of 4501. With recent changes in Swaziland’s na-
tional guidelines, the number of patients enrolled within
the primary population is expected to be lower than pro-
jected due to the change in ART initiation threshold.
The trial statisticians performed randomization of the
study sites before the start of the study. The 14 sites
have been grouped into seven pairs: four pairs were
grouped according to geographic proximity; two pairs
were grouped to coordinate the timing with operational
or logistical issues; and one pair was grouped and
excluded from the randomization so that it can transi-
tion to the intervention first to accommodate the social
science research timeline. The six remaining pairs will
be randomized into steps 2 to 7 when each site transi-
tions to the intervention stage, but the health workers,
Fig. 2 Stepped-wedge study design
Fig. 3 Trial flow diagram
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study participants, and study teams are blinded to the
timing to minimize bias.
Power calculations
Power calculations were undertaken to ensure that the
minimal detectable difference in the two primary
endpoint rates, given that the projected sample size was
well within the expected given prior literature [15]. For
one-year retention, 1160 patients in the primary study
population were projected to enroll during the EAAA
(intervention) phase and 2088 under the control phase
in the first 24 months to achieve a one-year follow-up.
Using the standard method for power calculations for
binary endpoints in stepped-wedge designs, with a 5%
two-tailed Type I error rate, an 80% power or more was
found to detect a 6–8 percentage point increase in the
one-year retention rate over a range of scenarios consid-
ered for the one-year retention rate in SOC from 40–
80% and an intra-cluster correlation coefficient (ICC) of
0–0.5, with no prior data available in Swaziland to allow
ICC estimation. It is well-known that the stepped-wedge
design is insensitive to the assumed value of the ICC
[15]. To be conservative, we considered a wide range.
Also, here, the minimum detectable effect sizes did not
vary over the range of ICCs considered.
For the six-month viral load suppression after ART
initiation endpoint, 1869 patients were projected to
enroll in the EAAA (intervention) phase and 1728 in the
control phase over the first 30 months to ascertain a six-
month viral load after ART initiation. Following the
methods as above, we found that there was 80% power
or more to detect a 7–8 percentage point increase in the
six-month viral suppression rate over a range of scenar-
ios considered for the six-month viral suppression rate
in standard of care of 20–70% and an intra-cluster
correlation coefficient of 0.10–0.20.
Study procedures
Community sensitization Community mobilization is
used to sensitize communities on early ART and create
demand for uptake of services. A comprehensive messa-
ging strategy was designed to address the complex
personal, cultural, social, and sexual considerations that
influence decisions around HIV testing and ART initi-
ation. Messages are delivered through a variety of
methods and activities, including sensitization meeting
with key community actors, including traditional leaders
to gain their support. Community dialogues targeting
community members are conducted using edutainment
providing HIV testing services for active case finding at
the community level.
Door-to-door visits where information, education, and
communication materials are delivered by trained
community-based volunteers. Community-based HTC is
provided during the community events and linkage to
care is ensured through working with expert patients
and HIV testing partners. Support groups are equipped
with skills and tools to provide treatment literacy to
PLHIV. These activities are conducted within a 20–30-
km radius around each study site.
Clinical procedures for ART initiation and follow-up
The study aims to promote a continuum of care and to
evaluate feasibility of an EAAA strategy within a public
sector health system setting. Therefore, the study will be
implemented in a public sector health system where
there is already an essential package of services available
through the current national ART program. The main
differences in the package of services delivered in the
standard of care vs. the intervention stage of the study
are outlined in Table 1 below.
Additional blood investigations will be conducted to
inform the measurement of the study endpoint, viral load
suppression, but these lab tests will be taken in both the
standard of care and intervention groups. Aside from the
eligibility criteria and the messaging used during pre-ART
counseling sessions, there will be no differences in the
package of follow-up services provided to patients
between the control and intervention study groups.
Per national guidelines, ART initiation takes place
within four weeks of HIV testing or two weeks of enroll-
ment at the trial clinic, unless delayed per clinician’s
guidance. All ART drugs used in the trial follow the
Swaziland adult HIV management guidelines. All indi-
viduals who are eligible for treatment will be initiated on
Swaziland’s recommended first-line ART regimen (TDF
+ 3TC + EFV), unless contraindicated when recom-
mended alternate regimens will be used per national
guidelines. These alternatives are: TDF + 3TC +NVP or
AZT + 3TC +NVP (when EFV cannot be used); ABC +
3TC + EFV or AZT + 3TC + EFV (when TDF cannot be
used); ABC + 3TC + EFV or d4T + 3TC + EFV (when
AZT cannot be used).
All patients in the control and intervention phase will
follow the nationally recommended follow-up schedule
for individuals who are on ART or enrolled in pre-ART.
Table 1 Key differences in package of services in control vs.
intervention stage for patients enrolled in the EAAA study
Service Control Intervention
Eligibility
criteria for
ART initiation
Current national
treatment
guidelines
All HIV-positive individuals who are
aged 18 years or older, excluding
pregnant or breastfeeding women,
who attend the health facilities will
be offered ART regardless of CD4.
Pre-ART
counseling
sessions
2–3 sessions prior
to ART initiation
Same-day counseling and ART
initiation if patient is ready. Continue
counseling after initiation.
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Laboratory procedures Routine viral load and drug
resistance testing are important to understand the impli-
cations and impact of the interventions. Patients in both
study groups will receive routine viral load and drug
resistance testing in addition to the routine standard of
care laboratory tests per the recommendation of and as
dictated by Swaziland’s National Comprehensive HIV
Package of Care, including: HIV test; CD4 test, full
blood count; AST/ALT; creatinine; and Hepatitis B
surface antigen.
Each patient will provide samples every six months for
viral load testing. For drug resistance testing, a pre-
treatment sample will be collected from each patient
upon study enrollment and at ART initiation. Upon
initial signs of ART failure (two consecutive viral load
>1000 copies/mL), a post-treatment sample will be
collected for drug resistance testing.
Data collection procedures The data for the clinical
endpoints will be collected at the facility on an ongoing
basis as individuals are enrolled into the study and
return for follow-up visits at the facility. Health workers
will collect data from individual study participants at
each site using the national chronic care file paper-based
data collection forms.
Where possible, the study will collect data from exist-
ing data sources (i.e. patient’s chronic care files, facility
registers) to inform the research. Data will also be
collected from individual study participants at each visit.
For data collected on-site outside of existing Swaziland
Ministry of Health procedures, paper-based data collec-
tion forms will be used. Two copies of this form are
kept: one copy in the patients’ clinical file and the
second copy as part of the study records.
An electronic database will also be developed to
organize all study-related data. Data clerks will be
responsible for the daily entry of data from paper forms
into the electronic database. All data will be encrypted
to ensure patient confidentially before, during, and after
the trial. The principal investigator, study statistician,
and data manager will have access to the final trial
dataset.
Care of patients at the end of the trial Individuals en-
rolled in this study and initiated on ART will continue
to receive care and treatment through Swaziland’s public
sector health system for the rest of their lives.
Trial outcomes
A multidisciplinary, mixed-methods approach will be
adopted to meet the study aim, including implementa-
tion science research, social science research, economic
evaluations and cost-effectiveness modeling, and inci-
dence modeling.
Implementation science
This is one of the first studies in the treatment-as-
prevention field that has been designed to answer critical
implementation questions (i.e. acceptance and retention
among patients initiated on ART at higher CD4 thresh-
olds), and determine the “real world” potential of this
new prevention intervention [9, 16–19]. In resource-
limited countries, ministries of health need guidance on
how to aggressively and effectively adopt the new guide-
lines and targets, and to understand what the changes
will mean for their programs and budgets. As such, this
study’s primary and secondary outcomes (Table 2) are
structured to assess the feasibility, acceptability, clinical
outcomes, affordability, and scalability of offering early
antiretroviral treatment to all HIV-positive individuals in
Swaziland’s public sector health system.
Table 2 Primary and secondary outcomes
Primary outcomes Definition
Retention Alive and in care at each 12-month time
point following enrollment
Viral suppression The proportion of individuals alive and in
care whose viral load is below 1000
copies/mL (virally suppressed) after six
months on treatment
Secondary outcomes Definition
Retention At each six-month time point following
enrollment
Viral suppression At each six-month time point following
enrollment
Mortality At each six-month time point following
enrollment
Visit adherence among those
initiated on ART
Proportion of missed visits as a number
of scheduled appointments among
ART-ineligible patients by end
of follow-up
Drug resistance Proportion of drug resistance among
ART-ineligible patients with two
virological failures who have received
genotype resistance testing
Tuberculosis Proportion of ART-ineligible patients
diagnosed with tuberculosis following
enrolment (recurrent and new incident)
ART uptake among those
who are eligible
Proportion of HIV-positive individuals
who are eligible for initiation who are
successfully initiated to ART within on
the day of, within two weeks, and one
and three months of becoming eligible
Cost per patient per year Average public and private healthcare
expenditures per patient
Patient satisfaction Average patient satisfaction
Provider satisfaction Average job satisfaction among the
professionals providing HIV treatment
Patients’ employment,
income, and education
Average patients’ employment, income,
and educational attainment
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Social science research
Social science research methods are used to triangulate
the study’s findings on ART initiation, adherence, and
retention; to help identify effect moderators by analyzing
throughout the implementation social and structural fac-
tors and differences in health service delivery that may
differently affect the uptake of services before and after
facilities have transitioned to EAAA; and to contribute
to a deeper understanding of reasons for delayed initi-
ation, non-adherence, and non-retention. These objec-
tives will be met by conducting mixed-methods research
in a sample of nine study sites including a random quan-
titative survey, semi-structured interviews with health
providers and patients, and participant observation.
The quantitative survey will be conducted with a
random sample of patients tested HIV-positive during
the control phase and during the intervention phase at
six and 12 months (T1, T2, T3, n = 380 per survey, 760
in total). The baseline survey will be conducted in
12 months and will include a random sample of HIV-
positive patients who have initiated ART less than
12 months prior to the interview. A follow-up survey
will be conducted six months after the site’s last day of
its first transition month with patients who were initi-
ated within six months of the site’s transition to the
EAAA strategy (intervention stage). The second follow-
up survey at 12 months after the site last day of its first
transition months will allow for the comparison of the
experiences of those being initiated on ART and adher-
ence before and after the intervention, at six months
and at 12 months of being on ART. Changes across
time of distal/proximate factors will be studied, in-
cluding sex, age, family context, socioeconomic status,
employment status, health-seeking history, gendered
decision-making patterns, and illness experience.
Outcomes will include ART initiation, adherence and
retention, patients’ experience of immediate ART ini-
tiation process (i.e. confidentiality, informed consent,
enacted stigma, disclosure strategies, and sexual and
reproductive health desires).
To assess health providers’ experiences and attitudes
about EAAA, semi-structured interviews will be
conducted with a limited number at two points in time:
the second month into the transition and then again
four months after the last transition month (informa-
tion-rich case sampling of those most involved in
EAAA). To understand reasons for delayed initiation,
non-adherence, and non-retention, qualitative in-depth
interviews will be conducted among a diverse sample of
50 HIV-positive individuals (ten interviews per category,
of which five are men and five are women) who have ini-
tiated ART. These interviews will take place at random
points of time during the intervention stage at different
stages of each individual’s cascade of care and treatment.
The categories include EAAA patients who delayed or
refused ART initiation and, identified through the EAAA
database, patients who are not virally suppressed after
six months on treatment, patients who are virally sup-
pressed after six months on treatment, patients who
have not been retained in care/on ART at six months,
and patients who have been retained in care/on ART at
six months.
Finally, at each of the sampled facilities, three weeks of
observation will be conducted of pre- and post-test
counselling, ART initiation, and adherence counselling:
at baseline before the site transitions to the intervention
stage, in the second month during transition, and seven
months after the first transition month. These observa-
tions will take place simultaneously with the baseline pa-
tient semi-structured survey interview, health provider,
and/or qualitative patient interviews to limit the time
spent at each site.
Economic evaluation
The MaxART study aims to quantify empirically the
causal impacts of EAAA on a range of important
economic outcomes, including healthcare expenditure,
resources use, and patients’ welfare. In addition, the
cost-effectiveness of the EAAA approach will be esti-
mated through a predictive economic evaluation. To this
end, a comprehensive costing study will be conducted,
which includes systematic assessments of both the gov-
ernment and private activities for EAAA and the unit
costs for these activities. As part of the costing study,
the national health sector budgets and expenditure
reports will be regularly reviewed and the data relevant
to EAAA will be recorded, such as provider salaries and
facility, supply chain, drug, and laboratory costs. A time-
and-motion study will also be conducted to determine
how much time healthcare providers spend on the dif-
ferent HIV treatment-related activities, including con-
sultation time, physical examination, counseling, and
interpreting laboratory results. Finally, patient exit inter-
views will be used to measure private healthcare expend-
iture and the patient and provider time required under a
EAAA protocol.
Incidence modeling
To inform the national policymaker’s interpretation of
the stepped-wedge trial, as well as long-term planning of
a national EAAA program, a mathematical model has
been developed to simulate the heterosexual transmis-
sion of HIV and the provision of ART in the catchment
area of the study sites and for Swaziland as a whole [20].
The objectives of the HIV incidence modeling compo-
nent of this study are twofold. First, a narrow, data-
driven simulation study will be conducted to estimate
the impact of the EAAA stepped-wedge trial on HIV
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incidence during the study period in the catchment area
of the study sites. Second, a larger, projection study will
be conducted to estimate the impact of a national EAAA
program on HIV incidence over three time horizons: (1)
five years, (2) ten years, and (3) 15 years (Oct 2016–Sept
2031) for the entire country of Swaziland.
Outcome indicators for both analyses are the inci-
dence rate ratio, number of HIV infections averted, the
number of HIV-negative life-years gained, the number of
life-years gained, and the number of additional person-
years of ART provided (only for the national-level ana-
lysis). Outcome indicators for the first analysis will be
calculated using model output from both the control
and EAAA phases of the clinics, weighted for the popu-
lation size of the clinic catchment area and the amount
of time spent in each phase. Besides population-average
outcome indicators, the outcome indicators stratified by
age group and gender will also be calculated.
For the estimation of the impact of a national EAAA
program on HIV incidence, two scenarios will be
contrasted against one another. In the control scenario,
the country will maintain its current national treatment
guidelines for the entire simulation period. In the
EAAA scenario, a shift to universal treatment will be
simulated from October 2016 onwards. The rates of
HIV diagnosis, ART initiation, viral suppression, and
program retention among HIV-positive patients with
CD4 cell counts > 500/mL in the intervention scenario
will be equal to those inferred from the narrow, data-
driven simulation study.
The epidemiological model will be calibrated to his-
toric data on key demographics (population growth rate,
crude birth and death rates, geographical population
density), historic HIV prevalence data (stratified by age
group and gender), historic ART program size data
(number of people on ART, by age group and gender),
and recent HIV incidence data, by age group and gender
[13]. As parameters for the sexual behavior in the model
population are typically difficult to estimate directly
from empirical data, due to selection bias and social
desirability bias in sexual behavior surveys, these model
parameters will be inferred through an iterative Approxi-
mate Bayesian Computation algorithm with wide prior
distributions [21].
Once the “model world” is deemed sufficiently resem-
bling of the real world, the “model trial” will be cali-
brated to the real trial by adjusting the hazard functions
for initiating ART and dropping out of the ART program
in order to match key summary statistics: the size of the
ART patient population by clinic, age group, gender,
baseline viral load, and baseline CD4 cell count. In
addition, the percentage of patients that is virally
suppressed six or more months after ART initiation will
be matched across all sites, during the period that the
sites were offering EAAA, as well as the percentage of
patients that are virally suppressed across all sites, dur-
ing the period that the sites were in the control phase.
Analysis
The primary analysis will follow the intent to treat ap-
proach, with each patient’s intervention status assigned
as the one in place at their facility at the time of study
enrollment. The log rank test, stratified by step time, will
be used to assess the statistical significance of any differ-
ences observed in one-year retention and six-month
suppression rates between the standard of care and early
access groups. Kaplan–Meier curves will be produced
and used to obtain point and interval estimates of the
cumulative incidence of the two primary endpoints at
the landmark time points. In the retention analysis, cen-
soring will occur only by administrative end of follow-up
or one year from enrollment, whichever happens first. In
the viral suppression analysis, only patients initiated to
ART who have at least six months of follow-up at the
time of administrative end of follow-up and at least one
viral load measured after that time will be included.
Thus, this endpoint will be interpreted as viral suppres-
sion given comprehensive clinical retention.
Censoring for this endpoint occurs at the minimum of
the date of the last viral load six months after ART initi-
ation, the administrative end of follow-up, and date of
death, whichever happens first. Secondary analysis of the
primary endpoints will include estimation of relative
risks, their 95% confidence intervals, and p values for
the intervention effects using the Cox proportional
hazards model, adjusting for potential measured con-
founders, including facility, sex, age, BMI, disclosure to
partner, occupation, education, baseline CD4, baseline
viral load, date of first HIV-positive test, baseline oppor-
tunistic infections, baseline WHO stage, and baseline
tuberculosis history. Additional analysis will adjust for
those variables which are repeatedly updated over time
as time-varying covariates, and will, in addition, consider
patient’s intervention status as time-varying, allowing for
the transition of facilities over time, as well as a time-
varying eligibility status, allowing for changes in national
guidelines and patient preferences.
Marginal structural models will be explored to adjust
for possible bias due to dependent censoring [22–24].
Modification of the intervention effects by age, sex,
baseline disease stage, facility type, and other hypothe-
sized modifiers will be explored by testing for interaction
using the partial likelihood ratio test and providing point
and interval estimates of stratum-specific intervention
effects. Longitudinal analysis of continuous variables
such as BMI, CD4, and viral load in relation to differ-
ences in the trajectories of change in these variables over
time by intervention group will be conducted under the
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generalized estimating equations framework, following
similar modeling strategies as described above [24].
Since one of our primary outcomes is retention, where
attrition can be considered the opposite of retention, the
intent to treat analysis is ideally situated to assess the
impact of the intervention on retention/attrition and can-
not be biased by it. However, six-month viral suppression
can be biased by differential non-retention. Therefore, in
secondary analysis, as recommended by Little et al. [25],
we will conduct a sub-study of non-retained clients to
better understand the reasons for this and to improve
their classification as dead, transferred, or truly lost to
follow-up for planned secondary analyses.
Discussion
The MaxART trial is designed to better understand the
“real world” complexities of implementing this treatment
for all approach. The quantitative and qualitative social
science research produced from this study will be essential
to understand the social and behavioral impact of offering
ART to HIV-positive individuals soon after diagnosis.
Community perception of the intervention and research
on how to best engage communities to support this inter-
vention will have an important influence on uptake,
linkages to care, retention, and adherence. Further, a com-
prehensive economic evaluation to assess how expanding
access to treatment will improve livelihoods and product-
ivity and, ultimately, decrease the cost to the health system
as a whole. Modeling will be used to also understand the
cost-effectiveness of the intervention, which is key evi-
dence for the Government of Swaziland’s national finan-
cial planning. This study has been designed to answer the
critical implementation questions posed by the Govern-
ment of Swaziland as the country works towards rolling
out a treatment for all approach across the country to turn
the tide on their epidemic.
Trial status
This trial is underway. Clients will be enrolled into the
study through August 2017.
Additional file
Additional file 1: SPIRIT Checklist MaxART Trial. SPIRIT checklist for the
MaxART EAAA Trial, indicating which manuscript page contains each
element of the study protocol. (DOCX 53 kb)
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